CN112876506A - Halin stimulant hapten, artificial antigen and antibody and preparation method thereof - Google Patents
Halin stimulant hapten, artificial antigen and antibody and preparation method thereof Download PDFInfo
- Publication number
- CN112876506A CN112876506A CN202110142265.5A CN202110142265A CN112876506A CN 112876506 A CN112876506 A CN 112876506A CN 202110142265 A CN202110142265 A CN 202110142265A CN 112876506 A CN112876506 A CN 112876506A
- Authority
- CN
- China
- Prior art keywords
- methylphosphonate
- hapten
- artificial antigen
- antibody
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 45
- 102000036639 antigens Human genes 0.000 title claims abstract description 45
- 108091007433 antigens Proteins 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title abstract description 10
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 26
- 230000003053 immunization Effects 0.000 claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 14
- 238000010168 coupling process Methods 0.000 claims abstract description 14
- 238000005859 coupling reaction Methods 0.000 claims abstract description 14
- 230000008878 coupling Effects 0.000 claims abstract description 13
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 13
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 11
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 11
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 claims abstract description 7
- -1 methyl dimethyl phosphonate Chemical compound 0.000 claims abstract description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 4
- 108010058846 Ovalbumin Proteins 0.000 claims abstract description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 4
- 229940092253 ovalbumin Drugs 0.000 claims abstract description 4
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 230000009260 cross reactivity Effects 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- NNKVPIKMPCQWCG-UHFFFAOYSA-N methamidophos Chemical compound COP(N)(=O)SC NNKVPIKMPCQWCG-UHFFFAOYSA-N 0.000 claims description 7
- RLBIQVVOMOPOHC-UHFFFAOYSA-N parathion-methyl Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C=C1 RLBIQVVOMOPOHC-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 6
- 239000005947 Dimethoate Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- YASYVMFAVPKPKE-UHFFFAOYSA-N acephate Chemical compound COP(=O)(SC)NC(C)=O YASYVMFAVPKPKE-UHFFFAOYSA-N 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- NGFFLHMFSINFGB-UHFFFAOYSA-N [chloro(methoxy)phosphoryl]oxymethane Chemical compound COP(Cl)(=O)OC NGFFLHMFSINFGB-UHFFFAOYSA-N 0.000 claims description 4
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 229960002684 aminocaproic acid Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012044 organic layer Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- 239000011248 coating agent Substances 0.000 description 19
- 238000000576 coating method Methods 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 13
- 238000000502 dialysis Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000447 pesticide residue Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003380 quartz crystal microbalance Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010897 surface acoustic wave method Methods 0.000 description 2
- XUNYDVLIZWUPAW-UHFFFAOYSA-N (4-chlorophenyl) n-(4-methylphenyl)sulfonylcarbamate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)OC1=CC=C(Cl)C=C1 XUNYDVLIZWUPAW-UHFFFAOYSA-N 0.000 description 1
- ZOCSXAVNDGMNBV-UHFFFAOYSA-N 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile Chemical compound NC1=C(S(=O)C(F)(F)F)C(C#N)=NN1C1=C(Cl)C=C(C(F)(F)F)C=C1Cl ZOCSXAVNDGMNBV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005893 Diflubenzuron Substances 0.000 description 1
- 239000005899 Fipronil Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000443 biocontrol Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940019503 diflubenzuron Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940013764 fipronil Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003854 herbicide residue Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002728 pyrethroid Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to the field of immunodetection, and in particular relates to a preparation method of a sarin stimulant methylphosphonate hapten, an artificial antigen and an antibody. The dimethyl methylphosphonate hapten has the advantages of simple structure, easy synthesis and environmental friendliness. The dimethyl methylphosphonate artificial antigen takes bovine serum albumin and ovalbumin as carrier proteins, and the synthesized artificial antigen has a large coupling ratio and good immunocompetence; and phosphonate groups are reserved in the artificial antigen, which is beneficial to preparing high-quality antibodies. The synthetic artificial antigen is used for obtaining the artificial methyl dimethyl phosphonate polyclonal antibody through animal immunization, and the antibody prepared by the method has high titer and strong specificity; can be used for developing the dimethyl methylphosphonate immunological rapid analysis technology, method and product.
Description
Technical Field
The invention relates to the field of immunodetection, in particular to a preparation method of a sarin stimulant methylphosphonate hapten, an artificial antigen and an antibody.
Background
In recent years, enzyme-linked immunosorbent assay (ELISA) is adopted to detect small molecular weight substances, and the detection method has the advantages of simplicity and convenience in operation, high sensitivity, strong specificity, rapidness and accuracy, and is rapidly applied to pesticide residue detection. ELISA analysis methods of methamidophos, methyl parathion, pyrethroid pesticides, fipronil pesticides, diflubenzuron pesticides and the like are reported in large quantity. With the rapid development of biotechnology and sensor technology, the ELISA method is widely applied to biocontrol bacteria monitoring, herbicide residue detection, pesticide residue (water and soil) detection and environmental pathogenic bacteria monitoring.
Dimethyl methylphosphonate (DMMP) is an organic phosphonate nerve agent with a molecular structure similar to that of the highly toxic chemical sarin. DMMP is often used as a mimetic of sarin because it is much less toxic than sarin. The traditional method for detecting DMMP is gas chromatography, has high sensitivity and good selectivity, but has the defects of expensive and heavy equipment, complicated sample pretreatment process, limitation to laboratory condition detection and the like. The portable DMMP detection method mostly uses a Surface Acoustic Wave (SAW) sensor, a Quartz Crystal Microbalance (QCM) sensor, a semiconductor sensor, etc., but also has the problems of poor specificity, poor environmental interference resistance and low detection sensitivity.
Disclosure of Invention
Based on the above, the invention aims to provide a sarin mimetic agent dimethyl methyl phosphonate (DMMP) hapten, an artificial antigen, an antibody and a preparation method thereof based on an ELISA method. The antibody prepared by the method can be further used for developing DMMP immune rapid analysis technology, method and product.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the invention provides an artificial hapten with DMMP as a framework, which has a molecular structure as follows:
or
A method for preparing methylphosphonate dimethyl ester hapten comprises the following steps:
s1, dissolving a carboxyl compound and potassium hydroxide in absolute methanol, then dropwise adding dimethyl chlorophosphate, stirring and heating after the dropwise adding is finished, and reacting for 10-15 hours;
s2, after the reaction is finished, distilling under reduced pressure to remove methanol, dissolving the residue with ethyl acetate, adding a sodium hydroxide solution, and finally adjusting the pH value of the reaction solution to 1-4 with hydrochloric acid;
s3, after the pH value is adjusted, extracting for many times by ethyl acetate, combining organic layers, washing by water, finally adding anhydrous magnesium sulfate, drying overnight, filtering, and distilling under reduced pressure to remove ethyl acetate to obtain a target product;
s4, purifying the target product in the step S3 by column chromatography, wherein the eluent used is a mixture of chloroform, ethyl acetate and acetic acid.
Further, the carboxyl compound is any one of p-hydroxyphenylpropionic acid and 6-aminocaproic acid.
Further, the molar ratio of chloroform to ethyl acetate to acetic acid in the eluent is 25-40:1-10:1
The invention provides an artificial antigen prepared by coupling the synthesized hapten and carrier protein and a preparation method thereof, wherein the artificial antigen is obtained by coupling reaction of the carrier protein and methylphosphonate dimethyl ester hapten.
The structure of the artificial antigen is as follows:
the coupling method is characterized in that the methylphosphonic acid dimethyl ester hapten reacts with N-hydroxysuccinimide under the action of dicyclohexylcarbodiimide to generate an activated ester derivative; the activated ester derivative reacts with an amino group on the carrier protein to form a conjugate which is linked by an amide bond.
Further, the carrier protein is bovine serum albumin and ovalbumin.
The invention provides a method for preparing a dimethyl methylphosphonate antibody by carrying out animal immunization experiments on the synthesized antigen, wherein the dimethyl methylphosphonate antibody is a polyclonal antibody, and the antibody is obtained by carrying out animal immunization experiments on the artificial antigen.
Furthermore, the antibodies do not show cross reactivity to small molecule competitors such as methamidophos, methyl parathion, acephate and dimethoate, and the 50% inhibition competitor concentration IC of the methamidophos, methyl parathion, acephate and dimethoate50Are all greater than 105ng/mL。
The invention has the beneficial effects that: as can be seen from the above description of the present invention, compared with the prior art, the present invention discloses methylphosphonate dimethyl ester hapten, artificial antigen, antibody and preparation method thereof for the first time. The hapten of the DMMP artificial antigen prepared by the method is easy to obtain, is environment-friendly, has low preparation cost of the artificial antigen, and simultaneously reserves phosphonate groups in the prepared artificial antigen, thereby being beneficial to preparing high-quality antibodies;
the dimethyl methylphosphonate artificial antigen is obtained by coupling bovine serum albumin and ovalbumin serving as carrier proteins with dimethyl methylphosphonate hapten, and has good immunocompetence;
the invention uses the synthesized artificial antigen to immunize animals, thereby obtaining the specific antibody with high titer and high sensitivity, and the antibody provides a new means for establishing a rapid, simple, convenient, cheap, sensitive and specific methyl dimethyl phosphonate detection method.
Drawings
FIG. 1 is a scheme showing the synthesis route of hapten in example 1 of the present invention.
FIG. 2 is a scheme showing the synthesis of hapten in example 2 of the present invention.
FIG. 3 is a mass spectrum of a hapten in example 1 of the present invention.
FIG. 4 is a mass spectrum of a hapten in example 2 of the present invention.
FIG. 5 is a scheme showing the synthesis route of artificial hapten in example 1 of the present invention.
FIG. 6 is a scheme showing the synthesis route of artificial hapten in example 2 of the present invention.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention.
The first embodiment is as follows:
(1) synthetic route for hapten (i):
weighing 2.125g (12.8mmol) of p-hydroxyphenylpropionic acid and 1.8g of KOH (32mmol), dissolving in 100mL of anhydrous methanol at 0 ℃, then dropwise adding 2.770g (19.2mmol) of dimethyl chlorophosphate, stirring and heating after dropwise adding, slowly raising the temperature to 65 ℃, and continuing stirring and reacting for 12 hours.
After the reaction, the reaction mixture was distilled under reduced pressure to remove methanol, to obtain an initial product, which was dissolved in 15mL of ethyl acetate, and then 15mL of a 2mol/L NaOH solution was added, followed by adjusting the pH to about 2.0 with concentrated hydrochloric acid.
The mixture was extracted with 3X 20mL of ethyl acetate, the aqueous layer was discarded, the ethyl acetate layers were combined, the ethyl acetate layer was washed with 2X 10mL of distilled water, dried over anhydrous magnesium sulfate overnight, and the ethyl acetate was distilled off under reduced pressure to give the desired product.
Purifying the target product by column chromatography, wherein the eluent is a mixed solution of chloroform, ethyl acetate and acetic acid, and the volume ratio is as follows: chloroform-ethyl acetate-acetic acid-30: 5:1, average yield 73%.
(2) Synthetic route for antigen H1-Protein
The small molecule hapten containing carboxyl reacts with N-hydroxysuccinimide under the action of Dicyclohexylcarbodiimide (DCC) to generate an activated ester derivative, and the activated ester derivative reacts with amino on carrier protein to form a coupling compound connected by an amide bond.
The synthetic route of the antigen H1-Protein is as follows:
the specific synthesis steps of the antigen are as follows:
0.33mmol of the synthesized hapten was weighed out and dissolved in 300. mu. L N, N-Dimethylformamide (DMF), 0.14mmol of N-hydroxysuccinimide (NHS in 300. mu.L DMF) and 24mg of N, N-dicyclohexylcarbodiimide (DCC in 300. mu.L DMF) were added and stirred at room temperature for lh, then overnight at 4 ℃ with formation of insoluble material.
The next day (centrifugation conditions: 10000 rpm, 30 minutes, 4 ℃), the supernatant was added to 5mL of a 4mg/mL protein (BSA or OVA) in PBS, and the mixture was reacted at 4 ℃ for 5 hours.
After the reaction, the reaction solution was filled into a dialysis bag and dialyzed against PBST solution with pH 7.4 at 4 ℃, and the dialysis procedure was as follows: clamping one end of the dialysis bag by a dialysis bag clamp; moving the solution to be dialyzed into a dialysis bag; clamping the other end of the bag by using a dialysis bag clamp, and checking whether the whole bag is closed or not; the solution was placed in a buffer 10 times the volume of the solution in the bag, slowly stirred with a magnetic stirrer to facilitate the solution exchange, and dialyzed for 60h, and the PBS solution was exchanged for 8 h.
And finally, accurately measuring the volume of the dialyzed solution, measuring the protein concentration and the binding ratio, subpackaging and storing at-20 ℃.
The hapten (I) was calculated to have a 75:1 coupling ratio to BSA and 42:1 coupling ratio to OVA, and to have a greater coupling ratio to carrier protein.
(3) Preparation of DMMP polyclonal antibody
DMMP polyclonal antibody is prepared by immunizing animals with the above synthesized immune antigen H1-BSA solution, and the method comprises the following steps:
healthy white rabbits with the weight of 2-3kg and the age of about 3 months are selected and bred in a standard experimental animal room, and the immunity is observed after one week.
Dissolving 2mg of antigen prepared in the early stage in 2mL of physiological saline, sucking the antigen into a 5mL disinfection syringe, adding 2mL of Freund's safe adjuvant (Freund's safe adjuvant is used for the first-time immunization, and Freund's unsafe adjuvant is used for the second-time immunization), mixing and emulsifying, connecting another 5mL disinfection syringe by a silicon rubber tube, pushing the two hands oppositely, mixing and emulsifying to a water-in-oil (W/O) state, injecting the mixture into the back of the white rabbit intradermally, and performing the first-time immunization, the second-time immunization, the third-time immunization, the fourth-time immunization, the fifth-time immunization; two weeks between the first and second immunizations, and three weeks between the other immunizations.
Blood testing is started after four times of immunization, namely 7 days to 10 days after four times of immunization, blood is collected from the marginal vein of the ear for 0.5mL to 1.0mL, the blood is kept stand for 2 hours at room temperature to solidify blood cells, the blood cells are centrifuged at 4000rpm, serum is taken for dilution in multiple proportion, and the titer of antiserum is checked by adopting an indirect enzyme-linked immunosorbent assay (ELISA).
After the titer is more than or equal to 50000:1, the rabbit carotid artery is subjected to blood sampling, a large amount of antiserum is prepared by a conventional method, and the antiserum is the DMMP polyclonal antibody and is frozen and stored after being subpackaged.
The optimal concentration of coating source was 2.5 μ g/mL, and the coating source was diluted with a coating buffer (carbonate buffer at pH 9.6).
The results show that the immunogen H1BSA midpoint titer (OD)492nm 1) is 12800:1, and the end point titer (P/N is more than or equal to 2) is 60000: 1.
(4) Artificial antibody specificity assay
Related compounds such as methamidophos, methyl parathion, acephate, dimethoate and the like are respectively used as small molecular competitors, and an established ELISA method is adopted to carry out indirect competitive inhibition test. Performing regression calculation according to the inhibition curveCompetitor concentration IC giving 50% inhibition (or binding)50And the cross-reactivity of each competitor with respect to hapten (I), the results of the assay are shown in Table 1.
TABLE 1 antibody specificity and Cross-reactivity
The results show that none of the related compounds selected in this example showed cross-reactivity to the antibody, IC of four competitors50Are all greater than 105ng/mL, indicating that the generated antibody has higher specific recognition capability.
Example two:
(1) synthetic route for hapten (II)
Synthesis of hapten (II) the reactants and the synthesis procedure were as in the synthesis of hapten (I) in example one, except that the reactant was 1.680g (12.8mmol) of 6-aminocaproic acid and the amount of base used was 0.9g of KOH (16 mmol).
(2) Synthetic route to antigen H2
The procedure for the synthesis of antigen H2-Protein was the same as that for antigen H1-Protein in example one.
The hapten (II) was calculated to have a 58:1 coupling ratio to BSA and a 61:1 coupling ratio to OVA.
(3) Preparation of DMMP polyclonal antibody
The DMMP polyclonal antibody is prepared by immunizing animals with the antigen H2-BSA solution synthesized above, and the synthesis steps and dialysis bag pretreatment steps are the same as those in example one.
After pretreatment by dialysis bags, the coupling ratio of hapten H2 to BSA was 58:1, and the coupling ratio of hapten H2 to OVA was 61: 1.
The antibody titer measurement result shows that the immunogen H2BSA middle point titer (OD)492nm 1) is 25600:1, and the end-point titer (P/N ≥ 2) is 100000: 1.
(4) Antibody specificity assay
Related compounds such as methamidophos, methyl parathion, acephate, dimethoate and the like are respectively used as small molecular competitors, and an established ELISA method is adopted to carry out indirect competitive inhibition test. The concentration of competitor IC which produced 50% inhibition (or binding) was calculated by regression calculations based on the inhibition curve50And the cross-reactivity of each competitor with respect to hapten (II), the results of the assay are shown in Table 2.
TABLE 2 antibody specificity and Cross-reactivity
The results show that none of the related compounds selected in this example showed cross-reactivity to the antibody, IC of four competitors50Are all greater than 105ng/mL, indicating that the generated antibody has higher specific recognition capability.
EXAMPLE III
Example one method for preparing DMMP polyclonal antibody by immunizing animal with immune antigen H1-BSA solution is to perform matrix titration by indirect non-competitive ELISA method to determine the binding titer of antiserum and coating antigen.
The immunogen is a conjugate of hapten and BSA, and the coating antigen is a conjugate of hapten and OVA corresponding to the immunogen. The coating concentrations were 20 μ g/mL, 10 μ g/mL, 5 μ g/mL, 2.5 μ g/mL, 1.25 μ g/mL, and 0.625 μ g/mL, respectively, and the coating was diluted with a coating buffer (carbonate buffer at pH 9.6). The specific operation steps are as follows:
a) antigen H1-Protein coating in example one: the enzyme-linked reaction plate was coated with serially diluted coating reagent at 100. mu.L/well overnight at 4 ℃.
b) Washing: the ELISA plate was returned to room temperature, the coating solution was discarded, the plate was washed with PBST solution five times for 3min each with 300. mu.L/well, and the plate was spin-dried.
c) And (3) sealing: the cells were then blocked with 200. mu.L of 0.1% gelatin in coating buffer per well in a 37 ℃ water bath for 100 min.
d) Washing: and b are the same.
e) Addition of antiserum: the antiserum was diluted to different concentrations in PBST dilutions, 100, 200, 400, 800, 1600, 3200, 6400, 12800, 25600 and 51200-fold, respectively, and a negative control serum and PBST blank were added. The antiserum and control solution were added in serial dilutions, 100. mu.L per well, and reacted in a 37 ℃ water bath lh.
f) Washing: and b are the same.
g) Adding an enzyme-labeled secondary antibody: and diluting goat anti-rabbit enzyme-labeled IgG with a proper concentration by using the sample diluent, adding 100 mu L of the diluted goat anti-rabbit enzyme-labeled IgG into each hole, and reacting for lh in a water bath at 37 ℃.
h) Washing: and b are the same.
i) Color development: add substrate solution, each well 150 u L, 37 degrees C color development 15 min.
j) And (4) terminating: 2mol/L of H is added to each well2SO4The reaction was stopped with 50. mu.L of the solution.
k) And (3) determination: the absorbance of each well at a wavelength of 492nm was measured with a microplate reader.
The corresponding optimal concentration of coating source was selected to be 2.5. mu.g/mL. OD at the optimum concentration of coating492And when the nm is 0.8-1.2, the corresponding antiserum dilution is the ELISA midpoint titer (working titer). When the OD value is twice of the OD value of the negative serum (namely P/N is more than or equal to 2, P is the absorbance value measured by a certain dilution factor of the substitute measurement serum, and N is the absorbance value measured by the corresponding dilution factor of the negative control), the corresponding antiserum dilution is the end point titer (positive titer). (negative serum OD)492nm＝0.1)。
The results show that immunogen H1BSA, coating antigen H1OVA, optimal coating antigen concentration is 2.5. mu.g/mL, the midpoint titer is 1: 12800 and the end point titer is more than 50000.
Example four:
the antigen H2-Protein in example II, the coating step is the same as that in example 3, and the result shows that the immunogen H2BSA and the coating antigen H2OVA have the optimal coating antigen concentration of 2.5 mu g/mL and the midpoint titer of 1: 25600, end point titer > 50000.
Example five:
before dialysis in the artificial antigen synthesis step of example one, the pH of PBST solution was adjusted with 2.0mol/L NaOH solution or 2.0mol/L HCl solution to prepare reaction solutions with pH values of 5.0, 6.2, 7.4 and 8.6, and then the dimethyl methylphosphonate standard solution and antiserum were diluted to perform indirect competitive ELISA.
| pH value | 5.0 | 6.2 | 7.4 | 8.6 |
| IC50(ng/mL) | 123 | 81 | 75 | 83 |
| Slope | -18.2 | -20.89 | -20.32 | -19.68 |
The results show that when the pH value is weak acidity, the competitive inhibition effect of dimethyl methylphosphonate on the antibody is weakened, and when the pH value is between 6.2 and 8.6, the pH value of the reaction system has no obvious influence on the competitive reaction.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other substitutions, modifications, combinations, changes, simplifications, etc., which are made without departing from the spirit and principle of the present invention, should be construed as equivalents and included in the protection scope of the present invention.
Claims (10)
1. A sarin mimetic agent methylphosphonate dimethyl ester hapten is characterized in that the molecular structural formula is shown as the following formula (I) or formula (II):
2. a method of preparing the methylphosphonate dimethyl ester hapten as claimed in claim 1, wherein: the methylphosphonate dimethyl ester hapten is synthesized by reacting a carboxyl compound and dimethyl chlorophosphate under an alkaline condition, wherein the formula (I) and the formula (II) respectively correspond to the carboxyl compound p-hydroxyphenylpropionic acid and 6-aminocaproic acid.
3. The method of claim 2, wherein the synthesis steps are as follows:
s1, dissolving a carboxyl compound and potassium hydroxide in absolute methanol, then dropwise adding dimethyl chlorophosphate, stirring and heating after the dropwise adding is finished, and reacting for 10-15 hours;
s2, after the reaction is finished, distilling under reduced pressure to remove methanol, dissolving the residue with ethyl acetate, adding a sodium hydroxide solution, and finally adjusting the pH value of the reaction solution to 1-4 with hydrochloric acid;
s3, after the pH value is adjusted, extracting for many times by ethyl acetate, combining organic layers, washing by water, finally adding anhydrous magnesium sulfate, drying overnight, filtering, and distilling under reduced pressure to remove ethyl acetate to obtain a target product;
s4, purifying the target product in the step S3 by column chromatography, wherein the eluent used is a mixture of chloroform, ethyl acetate and acetic acid.
4. The method of claim 3, wherein the molar ratio of chloroform to ethyl acetate to acetic acid in the eluent is 25-40:1-10: 1.
5. An artificial antigen prepared from the methylphosphonate dimethyl ester hapten as claimed in claim 1, wherein the molecular structural formula is as follows:
wherein the synthetic substrates of H1-Protein and H2-Protein correspond to haptens of formula (I) and formula (II) respectively in claim 1.
6. A method of producing the artificial antigen of claim 5, wherein the artificial antigen is obtained by coupling a carrier protein with the methylphosphonate hapten of claim 1.
7. The method of claim 6, wherein the methylphosphonate dimethyl ester hapten of claim 1 is reacted with N-hydroxysuccinimide under the action of dicyclohexylcarbodiimide to form an activated ester derivative, and the activated ester is reacted with an amino group on a carrier protein to form a coupling compound connected by an amide bond.
8. The method of claim 6 or 7, wherein the carrier protein is bovine serum albumin or ovalbumin.
9. A dimethyl methylphosphonate antibody prepared from the artificial antigen of claim 5, wherein the dimethyl methylphosphonate antibody is obtained by immunizing an experimental animal with the artificial antigen of claim 5.
10. The dimethyl methylphosphonate antibody of claim 9, wherein none of the small molecule competitors methamidophos, methyl parathion, acephate and Dimethoate show cross-reactivity to said antibody and the 50% inhibitory competitor concentration IC of methamidophos, methyl parathion, acemidophos, Dimethoate50Are all greater than 105ng/mL。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110142265.5A CN112876506B (en) | 2021-02-02 | 2021-02-02 | Halin stimulant hapten, artificial antigen and antibody and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110142265.5A CN112876506B (en) | 2021-02-02 | 2021-02-02 | Halin stimulant hapten, artificial antigen and antibody and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112876506A true CN112876506A (en) | 2021-06-01 |
| CN112876506B CN112876506B (en) | 2022-12-06 |
Family
ID=76052586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110142265.5A Active CN112876506B (en) | 2021-02-02 | 2021-02-02 | Halin stimulant hapten, artificial antigen and antibody and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112876506B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000236875A (en) * | 1999-02-23 | 2000-09-05 | Kankyo Meneki Gijutsu Kenkyusho:Kk | Malathion haptenic compound, antibody and measurement |
| CN101172984A (en) * | 2007-10-31 | 2008-05-07 | 江南大学 | Method of synthesizing general 2-methoxy phosphoric acid ester pesticide hapten |
| CN101334409A (en) * | 2008-07-22 | 2008-12-31 | 江南大学 | Methyl paraoxon enzyme-linked immunosorbent assay method |
| CN106543284A (en) * | 2016-11-08 | 2017-03-29 | 佛山市飞时达新材料科技有限公司 | A kind of preparation method and application of crotoxyphos, Carbicron and omethoate antibody |
-
2021
- 2021-02-02 CN CN202110142265.5A patent/CN112876506B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000236875A (en) * | 1999-02-23 | 2000-09-05 | Kankyo Meneki Gijutsu Kenkyusho:Kk | Malathion haptenic compound, antibody and measurement |
| CN101172984A (en) * | 2007-10-31 | 2008-05-07 | 江南大学 | Method of synthesizing general 2-methoxy phosphoric acid ester pesticide hapten |
| CN101334409A (en) * | 2008-07-22 | 2008-12-31 | 江南大学 | Methyl paraoxon enzyme-linked immunosorbent assay method |
| CN106543284A (en) * | 2016-11-08 | 2017-03-29 | 佛山市飞时达新材料科技有限公司 | A kind of preparation method and application of crotoxyphos, Carbicron and omethoate antibody |
Non-Patent Citations (1)
| Title |
|---|
| 李永详 等: ""二甲氧基硫代磷酸酯类农药多残留免疫分析方法研究"", 《分析化学》, vol. 38, no. 11, 30 November 2010 (2010-11-30), pages 1550 - 1555 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112876506B (en) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0668504B1 (en) | Quaternary ammonium immunogenic conjugates and immunoassay reagent | |
| CN101413955B (en) | ELISA test box for detecting zearalenone and preparing and detecting method thereof | |
| CN108640850B (en) | Malachite green hapten, artificial antigen and application of malachite green hapten and artificial antigen in fluorescence quantitative immunochromatography | |
| CN109307761B (en) | Indirect competitive ELISA method for detecting furaldehyde | |
| CN102206270B (en) | Saxitoxin artificial antigen and anti-saxitoxin antibody, their preparation methods and application | |
| CN110872344B (en) | Chloramphenicol complete antigen and preparation method and application thereof | |
| CN112876506B (en) | Halin stimulant hapten, artificial antigen and antibody and preparation method thereof | |
| CN111484448A (en) | Fluopyram hapten, preparation method and application thereof, and antibody and method for detecting fluopyram | |
| CN114315722B (en) | Preparation and application of tolfenpyrad artificial hapten and antibody thereof | |
| CN113968853A (en) | Hapten and artificial antigen of atropine alkaloid, and preparation method and application thereof | |
| CN111499637B (en) | Yohimbine hapten YHA, artificial antigen and antibody thereof, and preparation and application thereof | |
| CN111377888B (en) | Rhododendrin mollis toxin III hapten as well as preparation method and application thereof | |
| CN104655614A (en) | Chemical-luminescent ELISA method for detecting chlortoluron | |
| CN104655834A (en) | Chemical-luminescent enzyme-linked immunoassay method for detecting bentazone | |
| CN112358549A (en) | Preparation of dimethyl isotrichum monoclonal antibody and enzyme-linked immunosorbent assay method thereof | |
| JP3907919B2 (en) | Highly sensitive detection method for antigen or antibody | |
| CN113636954B (en) | Fipronil artificial antigen, preparation method and application | |
| CN114317450B (en) | Hybridoma cell strain secreting Flurobendiamide monoclonal antibody and application thereof | |
| CN114181108B (en) | Dendritic multiple hapten, artificial antigen and preparation method thereof | |
| CN111825759B (en) | Enzyme-linked immunosorbent assay method for indirectly detecting pirimiphos-methyl | |
| CN113897338B (en) | Hybridoma cell strain secreting 2,4-D monoclonal antibody and application thereof | |
| CN114456124B (en) | New cilastatin hapten, artificial antigen, antibody and preparation method and application thereof | |
| CN110724190B (en) | Naringenin antigen and preparation method and application thereof | |
| CN116789603A (en) | Novel carbendazim hapten, holoantim, antibody and preparation method and application thereof | |
| LI et al. | Development of anti-isoproturon polyclonal antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |